Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE

Macular Diseases

Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema

Int Ophthalmol.

Chen YY, Chen PY, Chen FT, Chen YJ, Wang JK

doi: 10.1007/s10792-017-0462-1.

Macular DiseasesRetinal Diseases

Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study

Am J Ophthalmol.

Fan W, Wang K, Ghasemi Falavarjani K, Sagong M, Uji A, Ip M, Wykoff CC, Brown DM, van Hemert J, Sadda SR

doi: 10.1016/

Macular Diseases

Effect of intravitreal ranibizumab on intraretinal hard exudates in eyes with diabetic macular edema

Am J Ophthalmol.

Srinivas S, Verma A, Nittala MG, Alagorie AR, Nassisi M, Gasperini J, Sadda SR

doi: 10.1016/j.ajo.2019.11.014.

RECOMMENDED

Retinal DiseasesSurgery and Intervention

Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-label Extension of RIDE and RISE Studies

Ophthalmology.

Sun JK, Wang PW, Taylor S, Haskova Z

doi: 10.1016/j.ophtha.2018.10.041.

Macular Diseases

Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial

JAMA Ophthalmol.

Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network

doi: 10.1001/

Macular DiseasesRetinal Diseases

Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema: A Subanalysis of the RESTORE (Extension) Study

JAMA Ophthalmol.

Karst SG, Deak GG, Gerendas BS, Waldstein SM, Lammer J, Simader C, Guerin T, Schmidt-Erfurth UM

doi: 10.1001/jamaophthalmol.

Macular Diseases

Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in patients with Diabetic Macular Edema

Am J Ophthalmol.

Fang M, Fan W, Shi Y, Ip MS, Wykoff CC, Wang K, Falavarjani KG, Brown DM, van Hemert J, Sadda SR

doi: 10.1016/j.ajo.

Macular Diseases

PRAGMATISM OF RANDOMIZED CLINICAL TRIALS ON RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA

Retina.

Stewart S, Yeong JL, Virgili G, Azuara-Blanco A, Lois N

doi: 10.1097/IAE.0000000000002476.

COMMENTED

Retinal Diseases

Retinal Nonperfusion Characteristics on Ultra-Widefield Angiography in Eyes With Severe Nonproliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy

JAMA Ophthalmol.

Nicholson L, Ramu J, Chan EW, Bainbridge JW, Hykin PG, Talks SJ, Sivaprasad S

doi: 10.1001/jamaophthalmol.

Related content

Comparison of efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema

Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study

Effect of intravitreal ranibizumab on intraretinal hard exudates in eyes with diabetic macular edema

Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-label Extension of RIDE and RISE Studies

Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial

Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema: A Subanalysis of the RESTORE (Extension) Study

Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in patients with Diabetic Macular Edema

PRAGMATISM OF RANDOMIZED CLINICAL TRIALS ON RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA

Retinal Nonperfusion Characteristics on Ultra-Widefield Angiography in Eyes With Severe Nonproliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy